<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk</h1>
<div class="graphic"><div class="figure"><div class="ttl">Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_single">Low risk disease (LRD)</td> <td class="subtitle1_single">Intermediate risk disease (IRD)</td> <td class="subtitle1_single">High risk disease (HRD)</td> </tr> <tr> <td>Most solid tumors</td> <td>Rare, highly chemotherapy-sensitive solid tumors (eg, neuroblastoma, germ cell tumor, small-cell lung cancer) with bulky or advanced stage disease</td> <td>N/A</td> </tr> <tr> <td>MM</td> <td>Plasma cell leukemia</td> <td>N/A</td> </tr> <tr> <td>CML</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>Indolent NHL</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>HL</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>CLL and WBC &lt;50 x 10<sup>9</sup>/L treated only with alkylating agents</td> <td>CLL treated with fludarabine, rituximab, or lenalidomide, or venetoclax and lymph node ≥5 cm<strong> or </strong>absolute lymphocyte count ≥25 x 10<sup><span style="font-size: 13px;">9</span></sup>/L, and/or those with high WBC ≥50 x 10<sup>9</sup>/L</td> <td>CLL treated with venetoclax and lymph node ≥10 cm, <strong>or</strong> lymph node ≥5 cm<strong> and </strong>absolute lymphocyte count ≥25 x 10<sup><span style="font-size: 13px;">9</span></sup>/L and elevated baseline uric acid.</td> </tr> <tr> <td rowspan="2">AML and WBC &lt;25 x 10<sup>9</sup>/L and LDH &lt;2 x ULN</td> <td>AML with WBC 25 to 100 x 10<sup>9</sup>/L</td> <td rowspan="2">AML and WBC ≥100 x 10<sup>9</sup>/L</td> </tr> <tr> <td>AML and WBC &lt;25 x 10<sup>9</sup>/L and LDH ≥2 x ULN</td> </tr> <tr> <td>Adult intermediate grade NHL and LDH within normal limits</td> <td>Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with LDH &gt; ULN, non-bulky</td> <td>Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with bulky disease and LDH ≥2 x ULN</td> </tr> <tr> <td>Adult ALCL</td> <td>Childhood ALCL stage III/IV</td> <td>N/A</td> </tr> <tr> <td>N/A</td> <td>Childhood intermediate grade NHL stage III/IV with LDH &lt;2 x ULN</td> <td>Stage III/IV childhood diffuse large B-cell lymphoma with LDH ≥2 x ULN</td> </tr> <tr> <td rowspan="2">N/A</td> <td rowspan="2">ALL and WBC &lt;100 x 10<sup>9</sup>/L and LDH &lt;2 x ULN</td> <td>Burkitt's leukemia</td> </tr> <tr> <td>Other ALL and WBC ≥100 x 10<sup>9</sup>/L and/or LDH ≥2 x ULN</td> </tr> <tr> <td>N/A</td> <td>Burkitt lymphoma and LDH &lt;2 x ULN</td> <td>Burkitt lymphoma stage III/IV and/or LDH ≥2 x ULN</td> </tr> <tr> <td>N/A</td> <td>Lymphoblastic lymphoma stage I/II and LDH &lt;2 x ULN</td> <td>Lymphoblastic lymphoma stage III/IV and/or LDH ≥2 x ULN</td> </tr> <tr> <td rowspan="2">N/A</td> <td rowspan="2">N/A</td> <td>Intermediate risk disease with renal dysfunction and/or renal involvement</td> </tr> <tr> <td>Intermediate risk disease with uric acid, potassium, and/or phosphate &gt; ULN</td> </tr> <tr> <td class="subtitle1_single" colspan="3">Prophylaxis recommendations</td> </tr> <tr> <td>Monitoring</td> <td>Monitoring</td> <td>Monitoring</td> </tr> <tr> <td>Hydration</td> <td>Hydration</td> <td>Hydration</td> </tr> <tr> <td>±Allopurinol</td> <td>Allopurinol</td> <td>Rasburicase*</td> </tr> </tbody></table></div><div class="graphic_footnotes">N/A: not applicable; MM: multiple myeloma; CML: chronic myeloid leukemia; NHL: non-Hodgkin lymphoma; HL: Hodgkin lymphoma; CLL: chronic lymphoid leukemia; WBC: white blood cell count; AML: acute myeloid leukemia; LDH: lactate dehydrogenase; ULN: upper limit of normal; ALCL: anaplastic large cell lymphoma; ALL: acute lymphoblastic leukemia.<br/>* Contraindicated in patients with a history consistent with glucose-6 phosphate dehydrogenase (G6PD) deficiency. In these patients, rasburicase should be substituted with allopurinol.</div><div class="graphic_reference">Cairo MS, Coiffier B, Reiter A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578. Copyright © 2010. Modified with permission of Blackwell Publishing Inc.</div><div id="graphicVersion">Graphic 57607 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
